logo
  

Teva Appoints Carlo De Notaristefani As President And CEO Of Global Operations

Teva Pharmaceutical Industries Ltd. (TEVA) announced that it has appointed Carlo De Notaristefani as President and Chief Executive Officer of Global Operations.

De Notaristefani has over 25 years of international experience with extensive technical, operational, manufacturing and P&L experience. Recently, De Notaristefani was at Bristol Myers Squibb (BMS) where he served as President, Technical Operations and Global Support Functions.

The company also appointed Aharon Yaari as the Executive Vice President to the newly created organization, Community and Institutional Affairs. Yaari joined Teva in 1981, and has served in significant key positions at Teva, such as Group Vice President, Global API, and most recently as Group Vice President, Teva Generics Systems.

In addition, as part of its strategic objectives, Teva has established an organization of Community and Institutional Affairs. This organization will be led by Yaari who will execute on Teva's global commitment to social responsibility, philanthropy, institutional affairs and academic relations.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Longmont Colorado -based Royal Crest Dairy is recalling 2% Chocolate Milk citing the potential to be contaminated with undeclared egg, a known allergen, the U.S. Food and Drug Administration said. The recall involves Farmer's 2% Reduced Fat Chocolate Milk Pints with the code date of AUG-22. ANI Pharmaceuticals, Inc. (ANIP) Monday announced a wider loss for the second quarter, despite a 52 percent surge in revenues. For the full year 2022, the company reiterated the adjusted earnings per share range, revenue guidance and raised Cortrophin revenue outlook. The company reported a quarterly... Shares of BioNTech SE were losing around 4 percent in the morning trading in Germany and around 5 percent in the pre-market activity on Nasdaq after the German Covid-19 vaccine maker reported sharp drop in profit and revenues for the second quarter. However, the company recorded strong growth in first-half results. Further, the company maintained BioNTech COVID-19 vaccine revenue guidance
Follow RTT